(Q35210201)

7 August 2017

1 reference

title

Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety, and biological immunomodulation (English)

1 reference

7 August 2017

1

Filip De Keyser

0 references

author name string

Dominique Baeten

2

1 reference

7 August 2017

Filip Van den Bosch

3

1 reference

7 August 2017

Elli Kruithof

4

1 reference

7 August 2017

Herman Mielants

5

1 reference

7 August 2017

Eric M Veys

6

1 reference

7 August 2017

publication date

1 August 2003

1 reference

Rheumatic Diseases Clinics of North America

7 August 2017

published in

1 reference

7 August 2017

volume

29

1 reference

7 August 2017

issue

3

1 reference

7 August 2017

page(s)

463-479

1 reference

Seronegative polyarthritis: a unified concept

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

The cutting edge of spondylarthropathy research in the millennium

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Bowel inflammation and the spondyloarthropathies.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Ileocolonoscopic findings in seronegative spondylarthropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

High frequency of silent inflammatory bowel disease in spondylarthropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Clinically silent inflammatory gut lesions in undifferentiated spondyloarthropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Focal up-regulation of E-cadherin-catenin complex in inflamed bowel mucosa but reduced expression in ulcer-associated cell lineage.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Distinctive activated cellular subsets in colon from patients with Crohn's disease and ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-alpha antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Case series of selective anti-tumor necrosis factor alpha therapy using infliximab in patients with nonresponsive chronic HLA-B27-associated anterior uveitis: comment on the articles by Brandt et al

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Needle arthroscopy of the knee with synovial biopsy sampling: technical experience in 150 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900052-8

7 January 2021

10.1016/S0889-857X(03)00052-8

Identifiers

DOI

1 reference

7 August 2017

1 reference